Yüksel Ürün: Does oncologic treatment for very advanced disease improve survival?

Yüksel Ürün shared a post on X:

“Does oncologic treatment for very advanced disease improve survival?

1. The study analyzed 78,446 adult patients with six common metastatic solid tumors. It found no significant survival benefit for patients receiving more systemic therapy for very advanced cancer.
2. There was no significant difference in survival between patients treated with high and low levels of systemic therapy. Oncologists should focus on honest communication about prognosis rather than offering additional therapy.
3. Efforts should help oncologists recognize when additional therapy is futile, improve communication about care goals, and align payment with better end-of-life care. Redirecting funds to home care and hospice services could enhance patient and caregiver satisfaction.”

Read further.
Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.